Relationship between mirtazapine dose and incidence of adrenergic side effects: An exploratory analysis

Michael Shuman, PharmD, BCPP; Athena Chukwu, PharmD; Nathan Van Veldhuizen, PharmD; Steven A. Miller, PhD

How to cite: Shuman M, Chukwu A, Van Veldhuizen N, Miller SA. Relationship between mirtazapine dose and incidence of adrenergic side effects: An exploratory analysis. Ment Health Clin [Internet]. 2019;9(1):41-7. DOI: 10.9740/mhc.2019.01.041.

Abstract

Introduction: Mirtazapine is an antidepressant with US Food and Drug Administration approval for management of major depressive disorder. Low doses of mirtazapine are often used for management of insomnia, with higher doses expected to provide more noradrenergic effect, and thus a higher degree of activation. If so, use of higher doses at bedtime may not be advisable and may worsen certain neuropsychiatric symptoms. No studies have been performed to evaluate these outcomes.

Methods: This study consisted of a retrospective review of data submitted to the US Food and Drug Administration’s Adverse Event Reporting System from January 1, 1995, to August 1, 2015. Cases that were deemed by study authors to represent activation of the noradrenergic system, and for which other confounders could not be identified, were included in the final analysis. The frequency of each specific adverse event was evaluated based on dose and compared to recent prescribing rates to determine if likelihood of a side effect increased with higher dose.

Results: The study identified 308 incidences of anxiety, agitation, delusion, hallucination, hypertension, insomnia, nightmare, or tachycardia. After controlling for frequency of prescribing at a given dose, there was a statistically significant increase in rates of tachycardia which correlated with dose. However, after correction for multiple comparisons, results were no longer significant.

Discussion: This study failed to support the hypothesis that mirtazapine is more activating at higher doses and appears to support the safety of increasing dose without increasing risk of noradrenergic side effects. Prospective studies will be necessary to confirm these findings.

Keywords: adverse drug reaction, depression, mirtazapine, posttraumatic stress disorder
overall increase in serotonin, norepinephrine, and dopamine levels, although not via the traditional blockade of reuptake transporters. Instead, it acts to modulate certain receptors that regulate levels of each of these neurotransmitters. For example, blockade of α2 adrenergic heteroreceptors on serotonergic neurons in raphe nuclei results in increased serotonin release, whereas blockade of the presynaptic α2 adrenergic autoreceptors located in the locus coeruleus increases release of norepinephrine. Furthermore, blockade of α2 adrenergic heteroreceptors increases dopaminergic activity in cortical regions. Mirtazapine has its highest affinity for histaminergic H1 receptors and serotonergic 5HT2A receptors (Kᵢ = 0.14 and 16, respectively). Blockade of H1 provides additional sedating and anxiolytic properties, whereas blockade of 5HT2A receptors provides increased dopaminergic activity. Mirtazapine has been shown to exhibit lower affinity for α1 receptors (Kᵢ = 141). However, this is based on analysis of human cortical tissue and thus may not necessarily translate to other brain regions or fully represent the activity of the drug in the human body.

In the clinical setting, it is assumed that such properties result in sedation at lower doses and less sedation at higher doses, as more α2 receptors become blocked and provide more of an activating effect through dopaminergic and noradrenergic signaling. The exact dose at which this occurs is not well delineated, nor are the effects on sedation conclusive. The few available data to support this are first based on comparisons between rates of sedation in European and US approval studies, with authors noting the difference in average dose and hypothesizing that this distinction was the source of the varying rates of sedation. There is additionally some evidence from the work of Grasmäder and colleagues, who reviewed the plasma levels and side effects of 45 patients receiving mirtazapine in a clinical setting. They noted a weak, inverse relationship between mirtazapine concentration and sedation. Low plasma concentrations were also associated with increased duration of sleep, although this effect did not persist beyond the first week.

These α2 adrenergic receptor effects may have implications when applied to other disease states. Krystal and Neumeister have identified α2 blockade as a potential modulator of PTSD symptoms and as an animal model of PTSD itself. There are case reports and anecdotal evidence alike supporting use of α2 agonists (ie, clonidine or guanfacine) as alternatives to the α2 blocker prazosin for treatment of PTSD-related nightmares. Given this, it would seem possible that mirtazapine’s α2 blockade provides concern when being used for treatment of PTSD and insomnia due to PTSD-related nightmares. Of note, the 2017 Veterans’ Affairs/Department of Defense clinical practice guideline for the management of PTSD and acute stress disorder no longer includes mirtazapine as having a recommendation for use (level B evidence), citing instead that there is insufficient evidence for or against use at this time. The stance is also supported by 2 other reviews but is in contrast to a recent network meta-analysis affirming its efficacy. A pharmacovigilance report was published in 2003 and described 50 cases of nightmares attributed to mirtazapine. However, doses were not provided. Thus, given its widespread use for insomnia, dosing guidance would be ideal in order to determine whether higher doses are more or less problematic.

Objectives

The goal of the current study was to determine whether activating side effects have been reported to the FDA’s adverse event reporting as attributed to mirtazapine and, if so, at which doses. These doses would then be compared to rate of reporting of a given adverse drug reaction (ADR) to determine whether a relationship existed between dose and noradrenergic activity, using incidence of activating side effects as a surrogate marker.

Methods

This was a retrospective review of pharmacovigilance reporting of mirtazapine through the FDA’s Adverse Event Reporting System (FAERS) from January 1, 1995, to August 1, 2015. The FAERS database is a collection of adverse events that is voluntarily reported to the FDA by health care providers, consumers, and manufacturers. Each case report is given a unique case number upon submission to the FDA in order to maintain the confidentiality and privacy of individuals. These cases included specific descriptors. To capture any activating effects reported to the FDA, authors agreed upon prespecified search terms related to noradrenergic stimulation via α2 antagonism. As a result, outcomes of interest included any incidences of abnormal dreams, anxiety, agitation, delusion, hallucination, hypertension, insomnia, nightmare, or tachycardia that resulted in an ADR to be submitted to the FDA between the dates listed above, for which mirtazapine was listed as a causative agent and a dose within the range of 3.75 and 90 mg was provided (Figure). Cases that listed one or more of these outcomes were reviewed by 1 of 3 investigators (M.S., A.C., or N.V.); any cases determined to be of questionable causality were then reviewed by all 3 investigators. Any adverse reactions that were reported outside of this time frame or were determined by the study investigators to be related to other factors (acute intoxication, withdrawal from a substance, serotonin syndrome) were excluded from the data, as were cases outside the age range of 18 to 65 years. Patients currently taking other psychotropic medications or those with known risk of similar side
effects, such as efavirenz, interferon, montelukast, prednisone, dextromethorphan, stimulants, cocaine, alcohol, or opioids, were excluded. Cases of attempted suicide or death by suicide were also excluded, given that those doses were unable to be quantified. Once the data were catalogued, descriptive statistics were used to determine whether incidence of a given side effect could be correlated to increasing dose. To control for the fact that increased incidence of side effects may be solely a function of increased prescribing rates, US prescribing data were obtained and \( \chi^2 \) tests were performed to analyze the data.

Within the United States, the Medical Expenditure Panel Survey (MEPS) is the primary source of data regarding health care use. Data are collected on a representative sample of households nationwide, estimated as \(~15,000\), and conducted via telephone on an annual basis. Utility of MEPS data for research purposes has already been established. Using household survey results, pharma-
cies are then contacted in order to obtain data, including National Drug Code, medication name, date filled, quantity and dose, and payment source. Using data program R version 3.4.2 and existing data available through the MEPS program, records were obtained for all individuals in the sample who were prescribed mirtazapine in calendar year 2013, because this was the most recent year of survey data available. There were no adjustments for patients taking half tablets or altering doses on their own; an assumption was made that written doses provided per pharmacy records were correct. Although the data are not designed to provide national estimates, they were able to be used to determine the ratio of doses prescribed at 7.5, 15, 30, and 45 mg. No doses above 45 mg were recorded in the MEPS sample, and thus statistical analysis was unable to be performed for cases reported at these doses. The relative prescribing rate at each dose (7.5, 15, 30, and 45 mg) was compared to the number of individuals reporting a given ADR at each dose, using Pearson $\chi^2$ coefficients to determine whether frequency of that ADR was associated with dose.

Results

During the time period from January 1, 1995, to August 1, 2015, a total of 14,719 adverse reactions were reported to the FDA listing mirtazapine as an active ingredient. Using initial search terms to identify the specific adverse events thought to be related to excess adrenergic activity, 2,269 cases were identified (Figure). After removing cases that met exclusion criteria, a total of 308 cases were included in final analysis and categorized by dose (Table 1). No association was found between dose of mirtazapine and likelihood of experiencing abnormal dreams, agitation, anxiety, delusions, hallucinations, hypertension, insomnia, or nightmares (Table 2).

We noted a linear association between dose and rate of tachycardia ($P = .043$). However, after using Bonferroni correction (setting $\alpha$ to .0056 to account for multiple

### Table 1: Cases stratified by mirtazapine dose and reported adrenergic side effect

| Symptom             | Average Dose, mg | Median Dose, mg | Dose <15 mg, n | Dose = 15 mg, n | Dose = 30 mg, n | Dose >30 mg, n | Total Cases, n |
|---------------------|------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Abnormal dreams     | 23.1             | 15             | 0              | 13             | 9              | 2              | 24             |
| Agitation           | 24.6             | 30             | 2              | 12             | 17             | 2              | 33             |
| Anxiety             | 23.6             | 15             | 4              | 26             | 19             | 7              | 56             |
| Delusion            | 30               | 30             | 2              | 4              | 4              | 4              | 14             |
| Hallucinations      | 23.9             | 15             | 4              | 15             | 12             | 6              | 37             |
| Hypertension        | 33.6             | 15             | 1              | 9              | 8              | 9              | 27             |
| Insomnia            | 26.8             | 15             | 2              | 19             | 15             | 11             | 47             |
| Nightmares          | 21.2             | 15             | 2              | 8              | 6              | 1              | 17             |
| Tachycardia         | 29               | 30             | 1              | 15             | 27             | 10             | 53             |

### Table 2: Relationship between mirtazapine dose and incidence of adrenergic side effects

| Symptom       | Likelihood Ratio$^a$ $\chi^2$ (P Value) | Pearson$^b$ $\chi^2$ (P Value) | Linear by Linear Association, Z Statistic (P Value) |
|---------------|----------------------------------------|---------------------------------|-----------------------------------------------|
| Abnormal dreams | 2.358 (.502)                           | 1.480 (.687)                   | $-0.298$ (.766)                             |
| Agitation      | 5.541 (.136)                           | 4.939 (.376)                   | $-0.424$ (.672)                             |
| Anxiety        | 1.872 (.599)                           | 2.330 (.507)                   | $-0.958$ (.338)                             |
| Delusion       | 3.737 (.291)                           | 6.389 (.094)                   | $-0.405$ (.685)                             |
| Hallucinations | 4.592 (.204)                           | 6.484 (.090)                   | $-0.380$ (.704)                             |
| Hypertension   | 1.874 (.599)                           | 2.236 (.525)                   | 0.982 (.326)                                |
| Insomnia       | 3.752 (.290)                           | 4.475 (.215)                   | 1.291 (.234)                                |
| Nightmares     | 2.635 (.451)                           | 3.690 (.297)                   | $-1.298$ (.194)                             |
| Tachycardia    | 6.520 (.089)                           | 6.415 (.093)                   | 2.028 (.043)$^b$                           |

$^a$Degrees of freedom = 3.

$^b$When Bonferroni correction applied, results no longer significant.

Ment Health Clin [Internet]. 2019;9(1):41-7. DOI: 10.9740/mhc.2019.01.041
comparisons and 9 separate primary end points), the result was not statistically significant.

Discussion

After excluding cases where mirtazapine was not a suspected cause or for which there were duplicate entries, a total of 308 cases of interest likely attributable to mirtazapine were identified out of 14,719 adverse events reported to the FDA regarding this agent. Although the overall rates of various neuropsychiatric/adrenergic side effects from mirtazapine were low within the population, this is in line with data collected by Biswas and colleagues, who identified, for example, 15 cases of abnormal dreams likely caused by mirtazapine, out of a total population of 33,554. Similarly, they found 14 cases of agitation, 10 cases of insomnia, 7 cases of worsening anxiety, and 4 cases of palpitations.

Despite the low numbers, actual rates may be much higher. There is a significant body of literature supporting the concept that spontaneous reporting, the method by which most surveillance systems collect their data, results in underreporting of adverse effects.

Rather than reviewing each year separately to examine prescribing rates and adverse event reporting rates within that same year, we pooled all of the adverse events for a specific dose across all years within the study period and compared them to prescribing rates within a given year, 2013. Although it is possible that the relative prescribing rates at each dose may vary from year to year, from an examination of year 2000 data there was little variance other than an increase in prescribing at the 45-mg dose. Thus, we feel that we can provide a reasonable estimate using data from a single year.

Although the receptor activity profile of mirtazapine has led to its use in the treatment of insomnia, we have previously raised concern for potential adverse effects, particularly a dose-dependent increase in the risk of nightmares. This study of cases contained in the FDA’s Adverse Event Reporting System where mirtazapine could be reasonably linked to a reported adverse effect found no relationship between dose of mirtazapine and incidence of nightmares. In addition, the incidence of abnormal dreams, agitation, anxiety, delusion, hallucination, hypertension, and insomnia were also not found to be related to dose. This result does not rule out mirtazapine having an effect on nightmares, because this has been previously identified through pharmacovigilance reporting. Rather, the effect may not be dose dependent, as it has previously been noted at doses of 7.5 and 15 mg. In addition, the effect may be modulated by receptor activity other than \( \alpha_2 \) adrenergic antagonism. Mirtazapine also has \( 5\text{HT}_2 \) antagonist properties that could potentially negate the nightmare-promoting effect of the \( \alpha_2 \) adrenergic antagonism, an effect previously described with cyproheptadine. As such, further study is required to justify the therapeutic role of mirtazapine in PTSD patients.

Our findings stand in general agreement with those of Grasmäder and colleagues, who identified, for example, 8 cases of mirtazapine overdose. Other than central nervous system depression, the most common adverse effect was tachycardia. Berling and Isbister identified 89 cases of overdose solely on mirtazapine, with 29 experiencing tachycardia and 32 noting hypertension. None experienced delirium or other neuropsychiatric effects other than altered mental status. LoVecchio et al and Waring et al report similar findings. As a retrospective study of pharmacovigilance reporting, this study is limited by observational error in the FDA’s Adverse Event Reporting System. However, the distribution of doses reported to FAERS is consistent with data obtained from MEPS and previous pharmacovigilance studies, indicating that it is likely representative of the larger population.

Conclusion

Despite the general understanding that \( \alpha_2 \) adrenergic effects of mirtazapine occur in a dose-dependent manner, there was no evidence for dose-dependent adverse effects other than a trend toward increased rate of tachycardia with higher doses. The incidence of adverse effects at a given dose therefore appears to reflect prescribing patterns, in that doses prescribed more frequently would have greater incidence of adverse effects. This includes no evidence of a dose-dependent effect on insomnia, nightmares, or other neuropsychiatric effects. A possible alternative explanation is that our data set simply lacked sufficient sensitivity to find a relationship. However, this alternative interpretation does not explain the detection of a dose-dependent effect of mirtazapine on the incidence of tachycardia.

These results seem to indicate that doses may be titrated upward at bedtime with low concern for insomnia or activating effects. There remains a safety signal for neuropsychiatric effects that is not necessarily dose

Ment Health Clin [Internet]. 2019;9(1):41-7. DOI: 10.9740/mhc.2019.01.041
Ment Health Clin [Internet]. 2019;9(1):41-7. DOI: 10.9740/mhc.2019.01.041

References

1. Drugs@FDA: FDA approved products [Internet]. Mirtazapine. Silver Spring (MD): US Food & Drug Administration [c2018; cited 2018 Oct 18]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppNo=020415

2. Kamphuis J, Taxis K, Schuing-Veninga CCM, Bruggeman R, Lancel M. Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in The Netherlands. J Clin Pharmacol. 2015;55(4):468-70. DOI: 10.1007/JCP.0000000000000338. PubMed PMID: 26035053.

3. VA/DoD clinical practice guideline for management of post-traumatic stress [Internet]. Washington: The Management of Post-Traumatic Stress Working Group [c2010; 2018 Oct 18]. Available from: https://www.healthquality.va.gov/ptsd-full-2010c.pdf.

4. De Boer T, Ruigt GSF, Berensen HHG. The 5z-selective adrenoceptor antagonist org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol Clin Exp. 1995;10(suppl 2):S107-18. DOI: 10.1002/hup.4700805.

5. Millan MJ, Gobert A, Rivet JM, Adhemar-Aucclair A, Cussac D, Newman-Tancredi A, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotoninergic, transmission by blockade of $alpha_2$-adrenergic and serotonin $5_{HT}$ receptors: a comparison with citalopram. Eur J Neurosci. 2003;12(3):1079-95. DOI: 10.1046/j.1460-9568.2000.00982.x. PubMed PMID: 12076339.

6. Deboer T, Maura G, Rairier M, Devos C, Wieringa J, Pinder R. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, org 3770 and its enantiomers. Neuropharmacology. 1988;27(4):399-408. DOI: 10.1016/0028-3908(88)90149-9.

7. Tanda G, Bassareo V, Di Chiara G. Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Pharmacology (Berl). 1995;62(2):127-30. DOI: 10.1007/bf02264659. PubMed PMID: 8741935.

8. Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol Clin Exp. 2006;21(2):137-25. DOI: 10.1002/hup.750. PubMed PMID: 16342227.

9. Barkin RL, Chor PN, Braun BG, Schwer WA. A trilogy case review highlighting the clinical and pharmacological applications of mirtazapine in reducing polypharmacy for anxiety, agitation, insomnia, depression, and sexual dysfunction. Prim Care Companion J Clin Psychiatry. 1999;1(5):142-5. DOI: 10.4088/pcc.v01n0502. PubMed PMID: 10145675.

10. Leonard SD, Karlamangla A. Dose-dependent sedating and stimulating effects of mirtazapine. Proc UCLA Healthc. 2015:19; 1-2.

11. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT$2A/C$ receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. 2009;29(9):1795-809. DOI: 10.1111/j.1460-9568.2009.06718.x. PubMed PMID: 19472334.

12. Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008;83(6):909-12. DOI: 10.1038/clpt.2008.52. PubMed PMID: 18388873. PubMed Central PMCID: PMC2671003.

13. Yamamoto Y, Valitato PA, van den Berg D-J, Hartman R, van den Brink W, Wong YC, et al. A generic multi-componental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations. Pharm Res. 2017;34(2):

14. Grassmäder K, Verwohlt PL, Kühn KU, Frahnert C, Hiemke C, Dragicevic T, et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry. 2005;38(3):113-7. DOI: 10.1055/s-2005-864120. PubMed PMID: 15902580.

15. Krystal JH, Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Res. 2009;1293:23-30. DOI: 10.1016/j.brainres.2009.03.044. PubMed PMID: 19332037. PubMed Central PMCID: PMC2671677.

16. Wendell KR, Maxwell ML. Evaluation of clonidine and prazosin for the treatment of nighttime posttraumatic stress disorder symptoms. Fed Pract. 2015;32(11):8-14.

17. McGrane IR, Shuman MD. Mirtazapine therapy for posttraumatic stress disorder. Harv Rev Psychiatry. 2018;26(1):36-41. DOI: 10.1097/hrp.0000000000000372. PubMed PMID: 29309320.

18. VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder [Internet]. Washington: The Management of Post-Traumatic Stress Disorder Working Group [c2017; cited 2018 Oct 18]. Available from: https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDptsDSCPFGfinal201418.pdf.

19. Lipinska G, Baldwin DS, Thomas KGF. Pharmacology for sleep disturbance in PTSD. Hum Psychopharmacol. 2016;31(2):156-63. DOI: 10.1002/hup.2522. PubMed PMID: 26856820.

20. Forman-Hoffman V, Cook Middleton J, Feltner C, Gaynes BN, Palmieri Weber R, Bann C, et al. Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality [2018 May]. Available from: https://effectivehealthcare.ahrq.gov/topics/ptsd-adult-treatment-update/research-2018.

21. Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2018;48(12):1975-84. DOI: 10.1017/s003329171700349x. PubMed PMID: 29254516.

22. Biswas PN, Wilton LV, Shakir SAW. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 23554 patients in England. J Psychopharmacol. 2003;17(1):121-6. DOI: 10.1177/0269881103017001716. PubMed PMID: 12680749.

23. Questions and answers on FDA’s Adverse Event Reporting System (FAERS) [Internet]. Silver Spring (MD): US Food and Drug Administration [c2016; cited 2018 Oct 18]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm.

24. Novak M, Shapiro CM. Drug-induced sleep disturbances. Drug Saf. 1997(16):133-49. DOI: 10.2165/00002018-199716020-00005. PubMed PMID: 9667124.

25. Medical Expenditure Panel Survey (MEPS) [Internet]. Rockville (MD): Agency for Healthcare Research and Quality [c2018; cited 2018 Oct 18]. Available from: http://www.meps.ahrq.gov/about_meps/overview/project.html.

26. Hill SC, Zuevaks SH, Zodet MW. Implications of the accuracy of MEPS prescription drug data for health services research. Inquiry. 2011;48(3):242-59. DOI: 10.5034/inquiryjrnl_48.3.04. PubMed PMID: 22235548.

27. Medical Expenditure Panel Survey [Internet]. FAQs [c2011; cited 2018 Oct 18]. Available from: https://meps.ahrq.gov/about_meps/faq_answers.jsp?FAQID=85&ChooseCategory=16&keyword=

28. R Core Team [Internet]. R: a language and environment for statistical computing [c2016; cited 2018 Oct 18]. Available from: https://www.R-project.org
29. Agency for Healthcare Research and Quality Center for Financing, Access, and Cost Trends [Internet]. MEPS HC-160A: 2013 prescribed medicines [c2015; cited 2018 Oct 18]. Available from: https://meps.ahrq.gov/data_stats/download_data/pufs/h160a/h160adoc.shtml

30. Agency for Healthcare Research and Quality. Number of people with purchase in thousands by prescribed drug, United States, 1996-2015: Medical Expenditure Panel Survey. Generated interactively: 2018 Feb 22.

31. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991;84(6):341-4. DOI: 10.1177/014107689108400612. PubMed PMID:2061900.

32. Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: systematic review. Clin Epidemiol. 2009;1:75-92. DOI: 10.2147/cep.s4775. PubMed PMID: 20865089.

33. Menon V, Madhavapuri P. Low-dose mirtazapine-induced nightmares necessitating its discontinuation in a young adult female. J Pharmacol Pharmacother. 2017;8(4):182-4. DOI: 10.4103/jppjp.116_17. PubMed PMID: 29472752; PubMed Central PMCID: PMC5820750.

34. Scarff JR. Thinking beyond prazosin when treating nightmares in PTSD. Curr Psychiatry. 2015;14(12):56-7.

35. Arora G, Sandhu G, Fleser C. Citalopram and nightmares. J Neuropsychiatry Clin Neurosci. 2012;24(2):E43. DOI: 10.1176/appi.neuropsych.11040096. PubMed PMID: 22772700.

36. Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry. 1998;59(5):233-5. DOI: 10.4088/jcp.v59n0505. PubMed PMID: 9632033.

37. Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. Clin Toxicol. 2014;52(1):20-4. DOI: 10.3109/15563650.2013.859264. PubMed PMID: 24228948; PubMed Central PMCID: PMC3894718.

38. LoVecchio F, Riley B, Pizon A, Brown M. Outcomes after isolated mirtazapine (Remeron™) supratherapeutic ingestions. J Emerg Medicine. 2008;34(1):77-8. DOI: 10.1016/j.jemermed.2007.03.006. PubMed PMID: 17976774.

39. Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol. 2007;45(1):45-50. DOI: 10.1080/15563650601005837.